This week's anticipated dividend increases feature six companies, averaging a 4.4% rise, with a median increase of 3.4%. My strategy involves investing in companies with consistent dividend growth and outperforming benchmarks, using data from the U.S. Dividend Champions and NASDAQ. I recommend SCHD for non-REIT investments and the Cohen & Steers REIT & Preferred Income Fund for REITs, both showcasing strong historical performance.
AES is projected to gain from expanding renewable generation and decreasing carbon emissions from its portfolio amid the impacts of declining wholesale prices.
How would you like to get paid to sit back and watch a stock you own take off? That's a scenario most investors would love.
One of the revelations of President Donald Trump's close friendship with Elon Musk was the huge electricity demand required to power Artificial Intelligence (AI).
Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and offer a promising avenue for total return.
The infrastructure sector is set for strong growth in the coming years. However, there are numerous attractive opportunities in the sector right now. I discuss five of them.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Stocks like SYK, LLY and AES recently announced dividend hikes.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tax-loss selling and short-covering dynamics create January Effect Rally opportunities, particularly in small and mid-cap stocks. The AES Corporation is undervalued, offers a 5.4% dividend yield, and is poised to benefit from AI data center energy demand. Actinium Pharmaceuticals, Inc. is a high-risk, high-reward biotech with strong cash reserves, undervalued stock, and a promising cancer treatment pipeline.
AES is projected to gain from expanding renewable generation and decreasing carbon emissions from its portfolio amid the impacts of declining wholesale prices.